Alan Jerry Korman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alan Jerry Korman has a total of 426 co-authors. Here are the top co-authors by number of shared publications:
- Mark Selby
Bristol-Myers Squibb (United States) 12 Redwood City, CA
34 shared publications - Ruth Y. Lan
Asher Biotherapeutics, Inc., South San Francisco, California. 1
25 shared publications Bryan R. McDonald
21 shared publicationsJack Lohre
21 shared publicationsJeff Houser
21 shared publications- Joseph R. Campbell
Bristol Myers Squibb, Redwood City, California
21 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Improving Anti–CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies
The Supplementary File contains figures S1 to S15 and Table S1, which contain supporting data for the experiments reported in the main manuscript.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Improving Anti–CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies
The Supplementary File contains figures S1 to S15 and Table S1, which contain supporting data for the experiments reported in the main manuscript.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Improving Anti–CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies
Purpose:The anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, ipilimumab (IPI), has shown clinical benefit across multiple tumor types, both as monotherapy and in combination with nivolumab or chemotherapy. However, not all tumors respond, and peripheral effects can lead to immune-related adverse events. We characterized three novel anti–CTLA-4 antibodies: peptide-masked [PROBODY conditionally activatable therapeutic (PB)], non-fucosylated (NF), and combined NF-PB (BMS-986288). Experimental Design:We evaluated the preclinical characteristics, including pharmacodynamics, tolerability, antitumor activity and efficacy, and peripheral immune responses, of these novel anti–CTLA-4 antibodies using in vitro systems, animal models, and human data. This includes data from preclinical mouse models of colorectal cancer as well as non–small cell lung cancer. Results:NF demonstrated greater T-cell priming and antitumor activity than both IPI and the unmasked PB antibody in cell-based assays and mouse models. Whereas the intact PB antibody showed minimal CTLA-4 binding and peripheral immune activation, unmasking restored its functional activity to levels comparable with those of IPI. Unmasked anti–CTLA-4 NF-PB retained the effectiveness of anti–CTLA-4 NF, and both molecules demonstrated more profound antitumor activity, increased effector memory T-cell response, and prolonged survival in mouse models compared with IPI. Anti–CTLA-4 NF-PB demonstrated reduced peripheral immune responses compared with anti–CTLA-4 NF or IPI in non-human primates and patients with solid tumors. Conclusions:Anti–CTLA-4 NF-PB has enhanced antitumor activity, efficacy, and reduced peripheral activity in preclinical models, and has the potential to provide therapeutic benefit in solid tumors.See related commentary by Galvez-Cancino et al., p. 3112
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Improving Anti–CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies
Purpose:The anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, ipilimumab (IPI), has shown clinical benefit across multiple tumor types, both as monotherapy and in combination with nivolumab or chemotherapy. However, not all tumors respond, and peripheral effects can lead to immune-related adverse events. We characterized three novel anti–CTLA-4 antibodies: peptide-masked [PROBODY conditionally activatable therapeutic (PB)], non-fucosylated (NF), and combined NF-PB (BMS-986288). Experimental Design:We evaluated the preclinical characteristics, including pharmacodynamics, tolerability, antitumor activity and efficacy, and peripheral immune responses, of these novel anti–CTLA-4 antibodies using in vitro systems, animal models, and human data. This includes data from preclinical mouse models of colorectal cancer as well as non–small cell lung cancer. Results:NF demonstrated greater T-cell priming and antitumor activity than both IPI and the unmasked PB antibody in cell-based assays and mouse models. Whereas the intact PB antibody showed minimal CTLA-4 binding and peripheral immune activation, unmasking restored its functional activity to levels comparable with those of IPI. Unmasked anti–CTLA-4 NF-PB retained the effectiveness of anti–CTLA-4 NF, and both molecules demonstrated more profound antitumor activity, increased effector memory T-cell response, and prolonged survival in mouse models compared with IPI. Anti–CTLA-4 NF-PB demonstrated reduced peripheral immune responses compared with anti–CTLA-4 NF or IPI in non-human primates and patients with solid tumors. Conclusions:Anti–CTLA-4 NF-PB has enhanced antitumor activity, efficacy, and reduced peripheral activity in preclinical models, and has the potential to provide therapeutic benefit in solid tumors.See related commentary by Galvez-Cancino et al., p. 3112
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , 3289-3308
Improving anti–CTLA-4 therapies through peptide masking and fragment crystallizable non‑fucosylation: preclinical characterization of three novel antibodies
Background: The anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, ipilimumab, has shown clinical benefit across multiple tumor types, both as monotherapy and in combination with nivolumab or chemotherapy. However, not all tumors respond, and peripheral effects can lead to immune-related adverse events. We characterized three novel anti–CTLA-4 antibodies: peptide-masked (PROBODY® conditionally activatable therapeutic [PB]), nonfucosylated (NF), and combined NF-PB (BMS-986288). Methods: We evaluated the preclinical characteristics, including the pharmacodynamics, tolerability, antitumor activity and efficacy, and peripheral immune responses, of these novel anti–CTLA-4 antibodies using in vitro systems, animal models, and human data. This includes data in preclinical mouse models of colorectal cancer as well as non-small cell lung cancer. Results: NF demonstrated greater T-cell priming and antitumor activity than both ipilimumab and the unmasked PB antibody in cell-based assays and mouse models. Whereas the intact PB antibody showed minimal CTLA-4 binding and peripheral immune activation, unmasking restored its functional activity to levels comparable with those of ipilimumab. Unmasked anti–CTLA-4 NF-PB retained the effectiveness of anti–CTLA-4 NF, and both molecules demonstrated more profound antitumor activity, increased effector memory T-cell response, and prolonged survival in mouse models compared with ipilimumab. Anti–CTLA-4 NF-PB demonstrated reduced peripheral immune responses than anti–CTLA-4 NF or ipilimumab in non-human primates and patients with solid tumors. Conclusion: Anti–CTLA-4 NF-PB has enhanced antitumor activity, efficacy, and reduced peripheral activity in preclinical models, and has the potential to provide therapeutic benefit in solid tumors.
- 16 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , 3289-3308
Open AccessImproving anti–CTLA-4 therapies through peptide masking and fragment crystallizable non‑fucosylation: preclinical characterization of three novel antibodies
Background: The anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, ipilimumab, has shown clinical benefit across multiple tumor types, both as monotherapy and in combination with nivolumab or chemotherapy. However, not all tumors respond, and peripheral effects can lead to immune-related adverse events. We characterized three novel anti–CTLA-4 antibodies: peptide-masked (PROBODY® conditionally activatable therapeutic [PB]), nonfucosylated (NF), and combined NF-PB (BMS-986288). Methods: We evaluated the preclinical characteristics, including the pharmacodynamics, tolerability, antitumor activity and efficacy, and peripheral immune responses, of these novel anti–CTLA-4 antibodies using in vitro systems, animal models, and human data. This includes data in preclinical mouse models of colorectal cancer as well as non-small cell lung cancer. Results: NF demonstrated greater T-cell priming and antitumor activity than both ipilimumab and the unmasked PB antibody in cell-based assays and mouse models. Whereas the intact PB antibody showed minimal CTLA-4 binding and peripheral immune activation, unmasking restored its functional activity to levels comparable with those of ipilimumab. Unmasked anti–CTLA-4 NF-PB retained the effectiveness of anti–CTLA-4 NF, and both molecules demonstrated more profound antitumor activity, increased effector memory T-cell response, and prolonged survival in mouse models compared with ipilimumab. Anti–CTLA-4 NF-PB demonstrated reduced peripheral immune responses than anti–CTLA-4 NF or ipilimumab in non-human primates and patients with solid tumors. Conclusion: Anti–CTLA-4 NF-PB has enhanced antitumor activity, efficacy, and reduced peripheral activity in preclinical models, and has the potential to provide therapeutic benefit in solid tumors.
- 30 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (115) , eady7328
Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling
Fc receptors mediate antibody effector functions. Immunoglobulin G (IgG), the predominant antibody in circulation and in clinical use, engages diverse Fc gamma (Fcγ) receptors differentially expressed across cell types. Here, we provide a comprehensive overview of Fcγ receptor and neonatal Fc receptor (FcRn) expression in humans, macaques, and mice. This analysis revealed substantial differences in Fcγ receptor diversity, cell-specific expression, and regulatory mechanisms that compromise the translation of mouse and macaque models for antibody research. To improve preclinical modeling, we generated a mouse in which humanized Fcγ receptors (FcγRI/CD64, FcγRIIA/CD32A, FcγRIIB/CD32B, FcγRIIIA/CD16A, and FcγRIIIB/CD16B), expressed under control of human promotors, replace their murine counterparts. This model also incorporates human FcRn to improve antibody pharmacokinetics. Humanization resulted in more faithful Fcγ receptor expression. We validated receptor functionality and demonstrated how cytokines modulate their expression. Together, this cross-species Fcγ receptor atlas and humanized mouse model can improve the preclinical evaluation of antibody-based therapeutics.
- 30 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (115) , eady7328
Cross-species cellular mapping and humanization of Fcγ receptors to advance antibody modeling
Fc receptors mediate antibody effector functions. Immunoglobulin G (IgG), the predominant antibody in circulation and in clinical use, engages diverse Fc gamma (Fcγ) receptors differentially expressed across cell types. Here, we provide a comprehensive overview of Fcγ receptor and neonatal Fc receptor (FcRn) expression in humans, macaques, and mice. This analysis revealed substantial differences in Fcγ receptor diversity, cell-specific expression, and regulatory mechanisms that compromise the translation of mouse and macaque models for antibody research. To improve preclinical modeling, we generated a mouse in which humanized Fcγ receptors (FcγRI/CD64, FcγRIIA/CD32A, FcγRIIB/CD32B, FcγRIIIA/CD16A, and FcγRIIIB/CD16B), expressed under control of human promotors, replace their murine counterparts. This model also incorporates human FcRn to improve antibody pharmacokinetics. Humanization resulted in more faithful Fcγ receptor expression. We validated receptor functionality and demonstrated how cytokines modulate their expression. Together, this cross-species Fcγ receptor atlas and humanized mouse model can improve the preclinical evaluation of antibody-based therapeutics.
- Open Access
- 16 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e013144
Endothelial cells as targets of immune checkpoint blockade
The tumor vasculature acts as the gatekeeper to the tumor microenvironment, thus regulating the ability of immune cells to roll, anchor, and cross the endothelium from blood to tissue. While the role of endothelial cells (EC) in T Cell migration and extravasation has been extensively studied, the ability of ECs to control T Cell function is less well appreciated. Several well-characterized regulators of T Cell function are expressed by ECs, while others are induced by soluble factors required for EC development and differentiation. Targeting the molecules expressed by immunomodulatory ECs may provide approaches to improve tumor immunotherapy.
- 16 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e013144
Open AccessEndothelial cells as targets of immune checkpoint blockade
The tumor vasculature acts as the gatekeeper to the tumor microenvironment, thus regulating the ability of immune cells to roll, anchor, and cross the endothelium from blood to tissue. While the role of endothelial cells (EC) in T Cell migration and extravasation has been extensively studied, the ability of ECs to control T Cell function is less well appreciated. Several well-characterized regulators of T Cell function are expressed by ECs, while others are induced by soluble factors required for EC development and differentiation. Targeting the molecules expressed by immunomodulatory ECs may provide approaches to improve tumor immunotherapy.
- Open Access
- 10 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (19) , eadm7515
CD8 + T cell targeting of tumor antigens presented by HLA-E
The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E–restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E–restricted CD8 + T cells and to express established tumor-associated antigens (TAAs) including prostatic acidic phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin. T cell responses to all three tumor antigens were comparable to viral antigen-specific responses with respect to frequency, duration, phenotype, epitope density, and MHC restriction. Thus, CMV-vectored cancer vaccines can bypass central tolerance by eliciting T cells to noncanonical epitopes. We further demonstrate that PAP-specific, MHC-E–restricted CD8 + T cells from RhCMV/PAP-immunized RM respond to PAP-expressing HLA-E + prostate cancer cells, suggesting that the HLA-E/NKG2A immune checkpoint can be exploited for CD8 + T cell–based immunotherapies.
- 10 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (19) , eadm7515
Open AccessCD8 + T cell targeting of tumor antigens presented by HLA-E
The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E–restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E–restricted CD8 + T cells and to express established tumor-associated antigens (TAAs) including prostatic acidic phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin. T cell responses to all three tumor antigens were comparable to viral antigen-specific responses with respect to frequency, duration, phenotype, epitope density, and MHC restriction. Thus, CMV-vectored cancer vaccines can bypass central tolerance by eliciting T cells to noncanonical epitopes. We further demonstrate that PAP-specific, MHC-E–restricted CD8 + T cells from RhCMV/PAP-immunized RM respond to PAP-expressing HLA-E + prostate cancer cells, suggesting that the HLA-E/NKG2A immune checkpoint can be exploited for CD8 + T cell–based immunotherapies.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Supp Methods and Legends S1-S10
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Supp Methods and Legends S1-S10
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Supp Methods and Legends S1-S10
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Supp Methods and Legends S1-S10